NVTA - Invitae Corporation

NYSE - NYSE Delayed Price. Currency in USD
8.42
+0.30 (+3.69%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close8.12
Open8.10
Bid0.00 x 1100
Ask0.00 x 2900
Day's Range8.04 - 8.59
52 Week Range4.35 - 10.44
Volume833,977
Avg. Volume944,601
Market Cap565.863M
Beta1.11
PE Ratio (TTM)N/A
EPS (TTM)-2.68
Earnings DateFeb 12, 2018 - Feb 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.75
Trade prices are not sourced from all markets
  • Invitae Study of 143,000 Patients Shows Importance of Routinely Including Deletion and Duplication Detection with Sequencing in Genetic Testing
    PR Newswire6 days ago

    Invitae Study of 143,000 Patients Shows Importance of Routinely Including Deletion and Duplication Detection with Sequencing in Genetic Testing

    SAN FRANCISCO, June 13, 2018 /PRNewswire/ -- Researchers from Invitae, one of the fastest growing genetics companies, today published findings from the largest analysis to date of genetic testing to identify deletions and duplications involving single genes using next-generation sequencing (NGS) techniques. The study found that these changes, also called exonic copy number variants (CNVs), are present in a substantial number of patients and suggested that CNV testing should be universally used in clinical genetic testing. With few exceptions, these types of exonic CNVs are not typically detectable or reported from cytogenetic methods such as whole-genome chromosomal microarrays.

  • ACCESSWIRE15 days ago

    Stock Performance Review on Exact Sciences and Three Other Medical Research Stocks

    Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Laboratories & Research stocks: DexCom Inc. (NASDAQ: DXCM), Exact Sciences Corp. (NASDAQ: EXAS), iKang Healthcare Group Inc. (NASDAQ: KANG), and Invitae Corp. (NYSE: NVTA).

  • Invitae to Present at the William Blair 2018 Growth Stock Conference
    PR Newswire20 days ago

    Invitae to Present at the William Blair 2018 Growth Stock Conference

    SAN FRANCISCO, May 30, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the William Blair 2018 Growth Stock Conference on Tuesday, June 12, 2018 at 4:10 p.m. Central / 5:10 p.m. Eastern / 2:10 p.m. Pacific in Chicago. Invitae Corporation (NVTA) is a genetics company whose mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae's goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time and lower prices.

  • Why This Genetics Stock Could Be a Gold Mine for Growth Investors
    Motley Foollast month

    Why This Genetics Stock Could Be a Gold Mine for Growth Investors

    Invitae reported $1.6 million in revenue in 2014. This year it expects more than $130 million.

  • Thomson Reuters StreetEventslast month

    Edited Transcript of NVTA earnings conference call or presentation 9-May-18 8:30pm GMT

    Q1 2018 Invitae Corp Earnings Call

  • Here's Why Invitae Rose as Much as 13.9% Today
    Motley Foollast month

    Here's Why Invitae Rose as Much as 13.9% Today

    The company's first-quarter 2018 performance exceeded even its own lofty expectations.

  • Associated Presslast month

    Invitae: 1Q Earnings Snapshot

    On a per-share basis, the San Francisco-based company said it had a loss of 66 cents. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018
    PR Newswirelast month

    Invitae Reports 169% Revenue Growth Driven by 150% Growth in Volume in First Quarter 2018

    -- Raising annual volume and revenue guidance -- -- Q1 2018 gross profit of $9.6M up from $1.0M in Q1 2017 -- -- Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific -- ...

  • The Zacks Analyst Blog Highlights: Audiocodes, Farmland Partners, Invitae, Global Medical and Glu
    Zackslast month

    The Zacks Analyst Blog Highlights: Audiocodes, Farmland Partners, Invitae, Global Medical and Glu

    The Zacks Analyst Blog Highlights: Audiocodes, Farmland Partners, Invitae, Global Medical and Glu

  • 5 of the Best Stocks Under $10 for 2018
    Zackslast month

    5 of the Best Stocks Under $10 for 2018

    Today we've highlighted five stocks that are currently trading for under $10 per share. All of these stocks currently sport a Zacks Rank #2 (Buy) or better, and the selected companies are showing signs of outpacing the market in the current calendar year.

  • Zacks.com featured highlights include: Del Taco, WellCare Health, Invitae, Visteon and Toll Brothers
    Zackslast month

    Zacks.com featured highlights include: Del Taco, WellCare Health, Invitae, Visteon and Toll Brothers

    Zacks.com featured highlights include: Del Taco, WellCare Health, Invitae, Visteon and Toll Brothers

  • Play Stocks With Rising P/E to Enjoy Solid Gains
    Zackslast month

    Play Stocks With Rising P/E to Enjoy Solid Gains

    Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

  • Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy
    PR Newswirelast month

    Sarepta and Invitae Expand Partnership to Advance Clinical Research in Duchenne Muscular Dystrophy

    "Our partnership with Invitae is important to advancing our clinical study objectives across our entire RNA-based platform," said Doug Ingram, Sarepta's President and CEO. DMD is a rare, fatal neuromuscular genetic disease that occurs in approximately one in every 3,500 – 5,000 males worldwide and is caused by a change or mutation in the gene that encodes instructions for dystrophin.

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in LRAD, Xencor, QuinStreet, Old Second, WesBanco, and Invitae — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, May 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of LRAD ...

  • Invitae to participate in two upcoming investor conferences, the Bank of America Merrill Lynch 2018 Heath Care Conference and the UBS Global Healthcare Conference
    PR Newswire2 months ago

    Invitae to participate in two upcoming investor conferences, the Bank of America Merrill Lynch 2018 Heath Care Conference and the UBS Global Healthcare Conference

    SAN FRANCISCO , May 3, 2018 /PRNewswire/ --  Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George , co-founder and chief executive officer of ...

  • Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA)
    PR Newswire2 months ago

    Invitae Announces New Program to Offer Genetic Testing to Aid Diagnosis of Spinal Muscular Atrophy (SMA)

    SAN FRANCISCO, April 27, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that it is launching a new program with Biogen, a leading biotechnology company, to offer genetic testing at no charge to patients suspected of having or clinically diagnosed with spinal muscular atrophy (SMA), a rare, progressive, genetic, neuromuscular disease. The program, SMA Identified, is the latest addition to Invitae's network of partnerships that connect patients and clinicians to treatment and research. "We know that genetic testing has the ability to accelerate the diagnostic process, and an early diagnosis could lead to earlier intervention and better medical outcomes for patients with SMA," said Robert Nussbaum, MD, chief medical officer of Invitae.

  • Invitae to Announce First Quarter 2018 Financial Results on May 9, 2018
    PR Newswire2 months ago

    Invitae to Announce First Quarter 2018 Financial Results on May 9, 2018

    SAN FRANCISCO, April 25, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetics companies, today announced that it will report its first quarter 2018 financial results on Wednesday, May 9, 2018 and will host a conference call and webinar that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and the reservation number for both is 9158119. Invitae Corporation (NVTA) is a genetic testing and information company.

  • Here's Why Invitae Stock Dropped as Much as 19.6% Today
    Motley Fool3 months ago

    Here's Why Invitae Stock Dropped as Much as 19.6% Today

    The company priced its public offering of shares -- at an all-time low.

  • Invitae Announces Pricing of Public Offering of Common Stock
    PR Newswire3 months ago

    Invitae Announces Pricing of Public Offering of Common Stock

    SAN FRANCISCO, March 28, 2018 /PRNewswire/ -- Invitae Corporation (NVTA) today announced the pricing on March 27, 2018 of an underwritten public offering of 11,111,111 shares of its common stock at a price to the public of $4.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $50.0 million.

  • This Explains Why Invitae Is Sinking Today
    Motley Fool3 months ago

    This Explains Why Invitae Is Sinking Today

    Traders head for the exits after the genetic testing company announces a dilutive capital raise.

  • Invitae Corporation (NYSE:NVTA): When Will It Breakeven?
    Simply Wall St.3 months ago

    Invitae Corporation (NYSE:NVTA): When Will It Breakeven?

    Invitae Corporation’s (NYSE:NVTA): Invitae Corporation, a genetic information company, processes DNA-containing samples, analyzes information related to patient-specific genetic variation, and generates test reports for clinicians and their patients in theRead More...

  • Benzinga3 months ago

    9 Stocks Moving In Monday's After-Hours Session

    Gainers: AnaptysBio Inc (NASDAQ: ANAB ) shares are up 8 percent on news of positive top-line proof-of-concept data for ANB020 in peanut allergy patients. Sears Hometown and Outlet Stores Inc (NASDAQ: SHOS ...

  • Invitae Announces Proposed Public Offering of Common Stock
    PR Newswire3 months ago

    Invitae Announces Proposed Public Offering of Common Stock

    SAN FRANCISCO, March 26, 2018 /PRNewswire/ -- Invitae Corporation (NVTA) today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.

  • Invitae expands network of patients in rare and ultra-rare diseases
    PR Newswire3 months ago

    Invitae expands network of patients in rare and ultra-rare diseases

    SAN FRANCISCO, March 22, 2018 /PRNewswire/ -- Invitae Corporation (NVTA), one of the fastest growing genetic information companies, today announced an expansion of its network of rare and ultra-rare patient registries in its Patient Insights NetworkTM (PIN) program to include five additional collaborations with leading advocacy groups across a variety of genetic conditions. The programs are designed to empower patients to be active participants in their networks and further expand Invitae's work to connect patients with rare genetic disorders to research, clinical trials and information on managing their condition. The first PIN to launch is led by No Stomach For Cancer, a leading research and advocacy organization focused on stomach cancer.